多西他赛配合替吉奥治疗复发转移性乳腺癌的临床疗效探析
|
摘要
目的探索和分析多西他赛配合替吉奥胶囊对复发转移性乳腺癌的临床治疗效果。方法对该院在2017年6月—2018年4月救治的晚期女性乳腺癌患者32例进行研究,给予静脉滴入多西他赛和替吉奥胶囊口服,3周为1个治疗周期,然后依据WHO恶性肿瘤疗效评估标准评估实际疗效,对于显示的不良反应,则依据WHO抗癌药物常见毒性分级要求与标准里面给定的0～Ⅳ度来予以评估。结果 32例患者都实施了超过2个周期的救治,其中,出现PD 7例、SD 7例、PR 15例、CR 3例;DCR达到78.13%,RR达到56.25%;且其中PR与ER显示阳性者的实际RR(59.37%)超出PR与ER显示阴性者(31.69%);另外,单病灶转移者的实际RR(61.32%)也超出多发病灶转移者(37.93%);患者不良反应都集中在Ⅲ以内,Ⅳ度仅有1例(3.13%)。其它不良反应则显示为恶心呕吐与脱发等,关节和肌肉痛的现象很少且给药停止后均能自行恢复,没有死亡现象。结论对显示转移的复发性乳腺癌来讲,选择科学的疗法不但可极大改善患者的健康与生存质量,使其生存时间得以延长,而且引起的不良反应较小、操作不复杂、服用后利用度高。其对该乳腺癌有着理想的维持治疗效用,值得临床推广应用。
Objective To explore and analyze the clinical therapeutic effect of docetaxel combined with tigeol capsule on recurrent metastatic breast cancer. Methods Thirty-two patients with advanced breast cancer who were treated in our hospital from June 2017 to April 2018 were enrolled in this study. Oral infusion of docetaxel and Teggio capsules was given orally, 3 weeks for 1 treatment cycle, then the actual efficacy was evaluated according to the WHO evaluation criteria for malignant tumors, and the adverse reactions shown were evaluated according to the common toxicity grading requirements of WHO anticancer drugs and the 0 to IV degrees given in the standard. Results 32 patients underwent more than 2 cycles of treatment, including 7 cases of PD, 7 cases of SD, 15 cases of PR, 3 cases of CR; DCR reached 78.13%, RR reached 56.25%; and PR and ER showed positive actual RR(59.37%) exceeded the PR and ER negative(31.69%); in addition, the actual RR(61.32%) of single lesion metastasis also exceeded the multi-focal metastasis(37.93%); patients with adverse reactions were concentrated within III, there is only one case(3.13%) of IV. Other adverse reactions were shown to be nausea, vomiting, and hair loss. The joint and muscle pain were rare and recovered spontaneously after administration. There was no death. Conclusion For the treatment of metastatic recurrent breast cancer, the choice of scientific therapy can not only greatly improve the health and quality of life of patients, but also prolong the survival time, and cause less adverse reactions, uncomplicated operation, high efficiency after taking. It has an ideal maintenance effect for this breast cancer and is worthy of clinical application.
Objective To explore and analyze the clinical therapeutic effect of docetaxel combined with tigeol capsule on recurrent metastatic breast cancer. Methods Thirty-two patients with advanced breast cancer who were treated in our hospital from June 2017 to April 2018 were enrolled in this study. Oral infusion of docetaxel and Teggio capsules was given orally, 3 weeks for 1 treatment cycle, then the actual efficacy was evaluated according to the WHO evaluation criteria for malignant tumors, and the adverse reactions shown were evaluated according to the common toxicity grading requirements of WHO anticancer drugs and the 0 to IV degrees given in the standard. Results 32 patients underwent more than 2 cycles of treatment, including 7 cases of PD, 7 cases of SD, 15 cases of PR, 3 cases of CR; DCR reached 78.13%, RR reached 56.25%; and PR and ER showed positive actual RR(59.37%) exceeded the PR and ER negative(31.69%); in addition, the actual RR(61.32%) of single lesion metastasis also exceeded the multi-focal metastasis(37.93%); patients with adverse reactions were concentrated within III, there is only one case(3.13%) of IV. Other adverse reactions were shown to be nausea, vomiting, and hair loss. The joint and muscle pain were rare and recovered spontaneously after administration. There was no death. Conclusion For the treatment of metastatic recurrent breast cancer, the choice of scientific therapy can not only greatly improve the health and quality of life of patients, but also prolong the survival time, and cause less adverse reactions, uncomplicated operation, high efficiency after taking. It has an ideal maintenance effect for this breast cancer and is worthy of clinical application.
引文
[1]江泽飞,宋三泰.紫杉醇在乳腺癌化疗临床应用的新进展[J].中国癌症杂志,2013,13(4):289-292.
[2]孙燕.内科肿瘤学[M].北京:人民卫生出版社,2017:994-996.
[3]孙燕,石远凯.临床肿瘤内科手册[M].5版.北京:人民卫生出版社,2017:142-145.
[4]Blagosklonnymv,Schulte T,Nguyen P,et al.Taxol induced apoptosis and phosphorylation of Bcl-2 protein involvescRaf-1 and represents a novel c-Raf-1 signal transduction pathway[J].Cancer Res,2017,56:1851-1854.
[5]王子平,孙燕,张湘茹,等.多西他赛治疗晚期乳腺癌的临床研究[J].中华肿瘤杂志,2016,28(6):468-470.
[6]Kondo N,Murakami Y,Uemura K,et al.Prognostic impact of dihy-dropyrimidine dehydrogenase expression on pancreatic adenocarcinomapatients treated with S-1-based adjuvant chemotherapy after surgicalresection[J].Journal of Surgical Oncology,2018,24(8):336-337.
[7]张丽敏,洪专.多西紫杉醇和顺铂联合用药对人乳腺癌MCF-7细胞h TERT及C-myc基因表达的影响[J].现代医学,2017,36(6):422-425.
[8]陈慧华,扬兰平.多西他赛联合卡培他滨治疗复发转移性乳腺癌36例临床观察[J].实用癌症杂志,2016,25(5):532-534.
[9]Toshiaki Saeki,Shigemitsu Takashima,Muneaki Sano.Aphase II study of S-1 in patients with metastatic breast cancer-A Japanese trial by the S-1 cooperative study group,breast cancer working group[J].Breast Cancer.2017,20(2):193.
[10]高小康,桑剑锋,苏磊,等.新辅助化疗对乳腺癌ER、PR表达的影响及其临床意义[J].现代医学,2017,38(5):180-181.
[2]孙燕.内科肿瘤学[M].北京:人民卫生出版社,2017:994-996.
[3]孙燕,石远凯.临床肿瘤内科手册[M].5版.北京:人民卫生出版社,2017:142-145.
[4]Blagosklonnymv,Schulte T,Nguyen P,et al.Taxol induced apoptosis and phosphorylation of Bcl-2 protein involvescRaf-1 and represents a novel c-Raf-1 signal transduction pathway[J].Cancer Res,2017,56:1851-1854.
[5]王子平,孙燕,张湘茹,等.多西他赛治疗晚期乳腺癌的临床研究[J].中华肿瘤杂志,2016,28(6):468-470.
[6]Kondo N,Murakami Y,Uemura K,et al.Prognostic impact of dihy-dropyrimidine dehydrogenase expression on pancreatic adenocarcinomapatients treated with S-1-based adjuvant chemotherapy after surgicalresection[J].Journal of Surgical Oncology,2018,24(8):336-337.
[7]张丽敏,洪专.多西紫杉醇和顺铂联合用药对人乳腺癌MCF-7细胞h TERT及C-myc基因表达的影响[J].现代医学,2017,36(6):422-425.
[8]陈慧华,扬兰平.多西他赛联合卡培他滨治疗复发转移性乳腺癌36例临床观察[J].实用癌症杂志,2016,25(5):532-534.
[9]Toshiaki Saeki,Shigemitsu Takashima,Muneaki Sano.Aphase II study of S-1 in patients with metastatic breast cancer-A Japanese trial by the S-1 cooperative study group,breast cancer working group[J].Breast Cancer.2017,20(2):193.
[10]高小康,桑剑锋,苏磊,等.新辅助化疗对乳腺癌ER、PR表达的影响及其临床意义[J].现代医学,2017,38(5):180-181.